AstraZeneca Rumored to Bid €176 Per Share for French Biotech Abivax Amid M&A Buzz
Abivax shares jump 6% on reports of AstraZeneca's €176-per-share offer for the French inflammatory disease drugmaker, adding to ongoing acquisition speculation.
/ 4 items
#ABVX↓
Eli Lilly Eyes €15 Billion Abivax Acquisition Amid Drug Success
Abivax shares surge 4% on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.
Eli Lilly Eyes French Biotech Abivax for Ulcerative Colitis Drug Deal
Pharma giant Eli Lilly considers acquiring French biotech Abivax for its promising ulcerative colitis treatment, expected to launch in 2027.
Wolfe Research Starts Coverage on Abivax with Outperform Rating and $176 Target
Wolfe Research initiates coverage of Abivax with an Outperform rating and $176 price target, citing strong potential for Crohn’s disease success and upcoming 2026 catalyst.